Skip to main content

Poly-Acrylic and Nucleic Acid Cobalt Hexamine Nanocomplexes: Characterization, RNase Protection and Inhibition of In Vitro Tumorigenicity in Soft Agar

Buy Article:

$107.14 + tax (Refund Policy)

Lack of protection to RNase and hence robust anti-cancer activity remains a challenge for RNA delivery. This article reports the characterization of novel polyacrylic acid (PAA) and RNA nanocomplexes with Cobalt hexamine (Cohex) and their inhibition of RNase degradation and anti-melanomic activity to cultured human melanoma cells (A375). Interaction between PAA, RNA and Cohex was determined by Nanodrop UV spectroscopy. Nanocomplex formation was confirmed by light scatter, zeta potential and nanoparticle tracking analysis. Finally, biochemical and anti-cancer activity was shown by RNase gel electrophoresis and soft agar assay. Cohex forms nanocomplexes with PAA and RNA where the RNA:Cohex inhibits RNA degradation by RNase and the PAA:Cohex potently inhibited human melanoma (A375) tumor formation in soft agar assay.

Keywords: COHEX; IN VITRO TUMORIGENICITY; NANOSIGHT; PAA; RNASE PROTECTION; UV/VIS

Document Type: Short Communication

Publication date: 01 November 2014

More about this publication?
  • Nanoscience and Nanotechnology Letters (NNL) is a multidisciplinary peer-reviewed journal consolidating nanoscale research activities in all disciplines of science, engineering and medicine into a single and unique reference source. NNL provides the means for scientists, engineers, medical experts and technocrats to publish original short research articles as communications/letters of important new scientific and technological findings, encompassing the fundamental and applied research in all disciplines of the physical sciences, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content